These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 21965371)

  • 41. Use of fibrin-based sealants and gelatin-matrix hemostats in laparoscopic liver surgery.
    Saif R; Jacob M; Robinson S; Amer A; Kei-Hui D; Sen G; Manas D; White S
    Surg Laparosc Endosc Percutan Tech; 2011 Jun; 21(3):131-41. PubMed ID: 21654294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cryoprecipitate: that old unknown.
    Blasi A; Beltran J; Pereira A; Puig L
    Rev Esp Anestesiol Reanim; 2015 Apr; 62(4):204-12. PubMed ID: 25561426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fibrinogen concentrate in the treatment of severe bleeding after aortic aneurysm graft surgery.
    Rahe-Meyer N
    Thromb Res; 2011; 128 Suppl 1():S17-9. PubMed ID: 22221846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.
    Rahe-Meyer N; Solomon C; Hanke A; Schmidt DS; Knoerzer D; Hochleitner G; Sørensen B; Hagl C; Pichlmaier M
    Anesthesiology; 2013 Jan; 118(1):40-50. PubMed ID: 23249928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood coagulation: hemostasis and thrombin regulation.
    Tanaka KA; Key NS; Levy JH
    Anesth Analg; 2009 May; 108(5):1433-46. PubMed ID: 19372317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
    He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
    Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia.
    Triulzi DJ; Blumberg N
    Yale J Biol Med; 1990; 63(1):1-7. PubMed ID: 2113328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cryoprecipitate. Patterns of use.
    Pantanowitz L; Kruskall MS; Uhl L
    Am J Clin Pathol; 2003 Jun; 119(6):874-81. PubMed ID: 12817436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of fibrinogen in massive injury.
    Maung AA; Kaplan LJ
    Minerva Anestesiol; 2014 Jan; 80(1):89-95. PubMed ID: 23857437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro.
    Thomas KA; Shea SM; Spinella PC
    Transfusion; 2021 Jun; 61(6):1943-1954. PubMed ID: 33755208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The blood bank physician as a hemostasis consultant.
    Sweeney JD
    Transfus Apher Sci; 2008 Oct; 39(2):145-50. PubMed ID: 18760674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery.
    Solomon C; Pichlmaier U; Schoechl H; Hagl C; Raymondos K; Scheinichen D; Koppert W; Rahe-Meyer N
    Br J Anaesth; 2010 May; 104(5):555-62. PubMed ID: 20348140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children.
    Moganasundram S; Hunt BJ; Sykes K; Holton F; Parmar K; Durward A; Murdoch IA; Austin C; Anderson D; Tibby SM
    Anesth Analg; 2010 Apr; 110(4):995-1002. PubMed ID: 20142345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy.
    Kikuchi M; Itakura A; Miki A; Nishibayashi M; Ikebuchi K; Ishihara O
    J Obstet Gynaecol Res; 2013 Apr; 39(4):770-6. PubMed ID: 23278972
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibrinogen Supplementation and Its Indications.
    Grottke O; Mallaiah S; Karkouti K; Saner F; Haas T
    Semin Thromb Hemost; 2020 Feb; 46(1):38-49. PubMed ID: 31574543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Less impairment of hemostasis and reduced blood loss in pigs after resuscitation from hemorrhagic shock using the small-volume concept with hypertonic saline/hydroxyethyl starch as compared to administration of 4% gelatin or 6% hydroxyethyl starch solution.
    Haas T; Fries D; Holz C; Innerhofer P; Streif W; Klingler A; Hanke A; Velik-Salchner C
    Anesth Analg; 2008 Apr; 106(4):1078-86, table of contents. PubMed ID: 18349176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%.
    De Lorenzo C; Calatzis A; Welsch U; Heindl B
    Anesth Analg; 2006 Apr; 102(4):1194-200. PubMed ID: 16551923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.
    Fenger-Eriksen C; Lindberg-Larsen M; Christensen AQ; Ingerslev J; Sørensen B
    Br J Anaesth; 2008 Dec; 101(6):769-73. PubMed ID: 18818192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
    Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
    Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of different hemostatic devices for severe liver bleeding: a randomized controlled animal study.
    Takács I; Wegmann J; Horváth S; Ferencz A; Ferencz S; Jávor S; Odermatt E; Rõth E; Weber G
    Surg Innov; 2010 Dec; 17(4):346-52. PubMed ID: 20870671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.